Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 287058, 6 pages
http://dx.doi.org/10.1155/2015/287058
Research Article

Effects of Cyclosporine on Reperfusion Injury in Patients: A Meta-Analysis of Randomized Controlled Trials

1Department of Cardiology, The General Hospital of Chinese People’s Liberation Army, No. 28, Fuxing Road, Beijing 100853, China
2Department of Geriatric Cardiology, The General Hospital of Chinese People’s Liberation Army, No. 28, Fuxing Road, Beijing 100853, China
3Yale Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511, USA

Received 19 October 2014; Accepted 12 January 2015

Academic Editor: Mengzhou Xue

Copyright © 2015 Kangxing Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. D. Mathers and D. Loncar, “Projections of global mortality and burden of disease from 2002 to 2030,” PLoS Medicine, vol. 3, no. 11, article e442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. L. Anderson, C. D. Adams, E. M. Antman et al., “2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 127, no. 23, pp. e663–e828, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Gomez, B. Li, N. Mewton et al., “Inhibition of mitochondrial permeability transition pore opening: translation to patients,” Cardiovascular Research, vol. 83, no. 2, pp. 226–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Braunwald and R. A. Kloner, “Myocardial reperfusion: a double-edged sword?” The Journal of Clinical Investigation, vol. 76, no. 5, pp. 1713–1719, 1985. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Garcia-Dorado, A. Rodríguez-Sinovas, M. Ruiz-Meana, and J. Inserte, “Protection against myocardial ischemia-reperfusion injury in clinical practice,” Revista Espanola de Cardiologia, vol. 67, no. 5, pp. 394–404, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Ma, H. Liu, S. R. Foyil et al., “Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury,” Circulation, vol. 125, no. 25, pp. 3170–3181, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Gao, H. Li, X. Feng et al., “α-enolase plays a catalytically independent role in doxorubicin-induced cardiomyocyte apoptosis and mitochondrial dysfunction,” Journal of Molecular and Cellular Cardiology, vol. 79, pp. 92–103, 2015. View at Publisher · View at Google Scholar
  8. A. P. Halestrap and A. P. Richardson, “The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 78, pp. 129–141, 2015. View at Publisher · View at Google Scholar
  9. F. Di Lisa, N. Kaludercic, A. Carpi, R. Menabò, and M. Giorgio, “Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66Shc and monoamine oxidase,” Basic Research in Cardiology, vol. 104, no. 2, pp. 131–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Z. Gerczuk and R. A. Kloner, “An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials,” Journal of the American College of Cardiology, vol. 59, no. 11, pp. 969–978, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Y. Lim, C. M. Messow, and C. Berry, “Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis,” British Journal of Pharmacology, vol. 165, no. 7, pp. 2034–2043, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Piot, P. Croisille, P. Staat et al., “Effect of cyclosporine on reperfusion injury in acute myocardial infarction,” The New England Journal of Medicine, vol. 359, no. 5, pp. 473–481, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ghaffari, B. Kazemi, M. Toluey, and N. Sepehrvand, “The Effect of prethrombolytic cyclosporine-a injection on clinical outcome of acute anterior st-elevation myocardial infarction,” Cardiovascular Therapeutics, vol. 31, no. 4, pp. e34–e39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Moher, B. Pham, A. Jones et al., “Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?” The Lancet, vol. 352, no. 9128, pp. 609–613, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Publisher · View at Google Scholar · View at Scopus
  16. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Morota, T. Manolopoulos, A. Eyjolfsson et al., “Functional and pharmacological characteristics of permeability transition in isolated human heart mitochondria,” PLoS ONE, vol. 8, no. 6, Article ID e67747, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Pahl, S. A. Miller, B. P. Griffith, and F. J. Fricker, “Occult restrictive hemodynamics after pediatric heart transplantation,” The Journal of Heart and Lung Transplantation, vol. 14, pp. 1109–1115, 1995. View at Google Scholar · View at Scopus
  19. L. A. Vricella, J. M. Karamichalis, S. Ahmad, R. C. Robbins, R. I. Whyte, and B. A. Reitz, “Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience,” Annals of Thoracic Surgery, vol. 74, no. 1, pp. 13–18, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Mewton, P. Croisille, G. Gahide et al., “Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction,” Journal of the American College of Cardiology, vol. 55, no. 12, pp. 1200–1205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Chiari, D. Angoulvant, N. Mewton et al., “Cyclosporine protects the heart during aortic valve surgery,” Anesthesiology, vol. 121, no. 2, pp. 232–238, 2014. View at Publisher · View at Google Scholar
  22. D. J. Hausenloy, G. Kunst, E. Boston-Griffiths et al., “The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial,” Heart, vol. 100, no. 7, pp. 544–549, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. R. S. Gill, D. L. Bigam, and P.-Y. Cheung, “The role of cyclosporine in the treatment of myocardial reperfusion injury,” Shock (Augusta, Ga), vol. 37, no. 4, pp. 341–347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. P. Halestrap, S. J. Clarke, and S. A. Javadov, “Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection,” Cardiovascular Research, vol. 61, no. 3, pp. 372–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. Q. Cai, G. F. Baxter, and D. M. Yellon, “Reduction of infarct size in isolated rat heart by CsA and FK506: possible role of phosphatase inhibition,” Cardiovascular Drugs and Therapy, vol. 12, no. 5, pp. 499–501, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Li, A. Iorga, S. Sharma et al., “Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A,” Anesthesiology, vol. 117, no. 4, pp. 836–846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Zhu, M. J. Rebecchi, Q. Wang, P. S. A. Glass, P. R. Brink, and L. Liu, “Chronic Tempol treatment restores pharmacological preconditioning in the senescent rat heart,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 304, no. 5, pp. H649–H659, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. R. J. Burns, R. J. Gibbons, Q. Yi et al., “The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis,” Journal of the American College of Cardiology, vol. 39, no. 1, pp. 30–36, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Krestnikova, A. Stulpinas, A. Imbrasaite, G. Sinkeviciute, and A. V. Kalvelyte, “JNK implication in adipocyte-like cell death induced by chemotherapeutic drug cisplatin,” The Journal of Toxicological Sciences, vol. 40, no. 1, pp. 21–32, 2015. View at Publisher · View at Google Scholar
  30. S. Wang, H. He, L. Chen, W. Zhang, X. Zhang, and J. Chen, “Protective effects of salidroside in the MPTP/MPP+-induced model of parkinson's disease through ros-no-related mitochondrion pathway,” Molecular Neurobiology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Appierto, P. Tiberio, M. G. Villani, E. Cavadini, and F. Formelli, “PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation,” Carcinogenesis, vol. 30, no. 5, pp. 824–831, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. R. DerSimonian and R. Kacker, “Random-effects model for meta-analysis of clinical trials: an update,” Contemporary Clinical Trials, vol. 28, no. 2, pp. 105–114, 2007. View at Publisher · View at Google Scholar · View at Scopus